Table 2 Postprogression overall survival among all pooled patients and by treatment cohort according to prognostic subgroup

Normal LDH + stage IIIC/M1a/M1b

240 (170)

11.2

(9.7–14.0)

23.1

(17.3–28.9)

41 (28)

10.5

(5.8–18.2)

23.1

(8.8–37.5)

129 (88)

10.6

(7.1–14.9)

23.8

(15.5–32.1)

70 (54)

13.3

(10.2–17.5)

22.8

(12.6–32.9)

Normal LDH + stage M1c + ppRx IT/TT

98 (74)

12.2

(10.3–16.1)

23.4

(14.5–32.3)

21 (14)

14.4

(6.9–33.1)

21.7

(0.0–44.2)

50 (39)

12.4

(10.3–18.4)

22.3

(10.3–34.3)

27 (21)

11.8

(8.5–18.4)

24.4

(7.8–41.1)

Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0

87 (72)

8.2

(6.0–10.6)

6.8

(0.7–13.0)

19 (13)

8.5

(3.2–21.4)

8.6 (0.0–24.4)

53 (45)

7.7

(5.5–13.2)

6.0

(0.0–13.6)

15 (14)

8.1

(5.8–14.1)

6.7

(0.0–19.3)

Normal LDH + stage M1c + ppRx other + ECOG PS at PD > 0

77 (71)

3.6

(2.6–4.6)

4.5

(0.0–9.4)

11 (10)

3.2

(1.3–5.4)

0.0

(0.0–0.0)

45 (41)

4.1

(3.2–6.2)

5.7

(0.0–13.0)

21 (20)

3.0

(1.6–8.3)

4.8

(0.0–13.9)

Elevated LDH (≤ 2 × ULN) + ppRx IT/TT

79 (67)

8.1

(6.7–12.9)

11.4

(3.7–19.2)

19 (17)

9.2

(3.4–17.1)

10.5

(0.0–24.3)

42 (34)

9.6

(7.0–17.2)

14.1

(2.8–25.5)

18 (16)

6.6

(4.3–15.3)

11.1

(0.0–25.6)

Elevated LDH (≤ 2 × ULN) + ppRx other

214 (186)

4.2

(3.5–5.0)

5.0

(1.1–8.8)

44 (35)

5.5

(4.1–11.9)

8.4

(0.0–18.9)

113 (95)

4.1

(2.9–4.9)

8.6

(2.8–14.3)

57 (56)

4.0

(3.0–5.4)

0.0

(0.0–0.0)

Elevated LDH (> 2 × ULN)

160 (150)

2.3

(1.8–2.7)

2.7

(0.0–5.5)

33 (29)

2.4

(1.5–3.6)

NE

(NE–NE)

93 (89)

2.4

(1.8–3.0)

2.5

(0.0–5.8)

34 (32)

1.8

(1.2–3.3)

NE

(NE–NE)